embalaje : 50mg
Teléfono : +1 850 650 7790
Synonyms: RTV, ABT 538, Abbott 84538, A 84538
| Description | Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450. |
| In vivo | Ritonavir is a potent inhibitor of CYP3A-mediated biotransformation (terfenadine hydroxylation, IC50 of 0.14 mM; 17alpha-ethynylestradiol 2-hydroxylation, IC50 of 2 mM; nifedipine oxidation, IC50 of 0.07 mM).Ritonavir is a a potent inhibitor of CYP3A4-mediated testicular 6β-hydroxylation (Ki: 19 nM), and also inhibited hydroxylation by toluenesulfonylurea (IC50: 4.2 μM).Ritonavir also inhibited CYP2D6 (IC50: 2.5 mM) and CYP2C9/10 (IC50: 8.0 mM)-mediated responses.Ritonavir Ritonavir increased the cellular activity of uninfected human PBMC cultures.Ritonavir inhibited p-glycoprotein-mediated saquinavir solubilization (IC50: 0.2 μM), suggesting that Ritonavir has a high affinity for p-glycoprotein.Ritonavir significantly inhibited the metabolism of human hepatic microsomes ABT-378 (Ki: 13 nM). Ritonavir binding to ABT-378 ( in 3:1 and 29:1 ratios) was able to inhibit CYP3A (IC50: 1.1 and 4.6 μM). In cultures of uninfected human PBMCs, Ritonavir significantly reduced the susceptibility of PBMCs to apoptosis (associated with low levels of caspase-1 expression), decreased caspase-3 activity, and reduced membrane-bound protein staining. Ritonavir inhibited the induction of tumor necrosis factor produced by PBMCs and monocytes at nontoxic concentrations in a time- and dose-dependent manner. |
| Synonyms | RTV, ABT 538, Abbott 84538, A 84538 |
| Molecular Weight | 720.94 |
| Formula | C37H48N6O5S2 |
| Cas No. | 155213-67-5 |
| Smiles | CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1 |
| Relative Density. | 1.239 g/cm3 |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 242.5 mg/mL (336.37 mM), Heating is recommended.  Ethanol: 7.21 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2.5 mg/mL (3.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
